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Several neuroimmunological registries have been established 
in	Germany	during	the	last	10	years.	The	common	aim	is	to	
investigate	the	course	of	different	diseases,	mainly	under	var-
ious therapeutic conditions, to identify predictive factors as 
well	as	the	side	effects	of	immunomodulating	therapies.	Six	






dinates and mediates between scientists and clinicians and acts 
as a platform for the development of guidelines and proce-
dures.	The	neuromyelitis	optica	study	group	(NEMOS)	has	es-
tablished a national registry for patients with neuromyelitis 
optica and neuromyelitis optica spectrum disorders. In addition 
to 22 academic hospitals, 17 regional hospitals and several 
practices are participating. Currently, 250 patients are enrolled. 
Moreover, NEMOS is now establishing a prospective patient 
cohort	(NationNMO)	within	the	competence	network	multiple	
sclerosis. Current research focuses on treatment strategies for 
relapses	and	interval	therapy	of	neuromyelitis	optica.	The	com-
petence network multiple sclerosis has initiated a multi-center, 
prospective cohort study of patients with clinically isolated 
syndrome	(CIS)	or	relapsing-remitting	multiple	sclerosis	(MS)	
(NationMS),	with	the	aim	of	long-term	follow-up	and	clinical	
and paraclinical characterization of the patients. Between Au-
gust 2010 and December 2014, 1,212 patients in 22 universi-
ty und non-university centers were enrolled in the NationMS 








comprehensively, with the main purpose of establishing a per-
manent data repository for healthcare research while ensuring 
the collection, storage and provision of data over decades and 
enabling the description of long-term outcomes. Currently, 
more	than	170	German	centers	are	participating	and	over	
48,000 patients are enrolled in the registry. Since 2013, the 
competence network multiple sclerosis has established the 
immunotherapy	registry	REGIMS	with	the	objective	to	obtain	
information on incidence, type and characteristics of adverse 
events of new immunomodulating therapies for patients with 
multiple sclerosis or clinical isolated syndrome. As of January 
2017 more than 700 patients have been recruited from 36 ac-
tive	centers.	The	German	Multiple	Sclerosis	and	Pregnancy	
Registry aims to obtain safety information of disease modifying 
drug exposure during pregnancy. In addition to safety aspects, 
disease course during pregnancy and postpartum and the iden-
tification	of	predictors	of	disease	activity	are	investigated.	Dur-
ing the last ten years 1,500 pregnant MS patients were pro-
spectively enrolled in the registry and at least 250 new 
pregnancies	are	followed	every	year.	These	six	registries	make	
an	important	epidemiological	and	scientific	contribution.	Nu-
merous colleagues from clinics and practice support these 
registries.	The	objective	is	the	closer	understanding	of	the	dis-
ease	course,	the	influence	of	therapeutic	decisions	and	thus	
the improvement of counseling and care.
nomenology, prognostic implications, frequency of tumor associ-
ation and response to therapies is a task that can only be 
particularly	addressed	by	large	clinical	registries.	German	patients	











proaches. For this purpose, a representative interactive homepage 
(www.generate-net.de)	was	created,	an	internet-based	communi-
cation forum was set up for members, a national patient registry 
was established, central and decentralized biomaterial collections 




spective cohort study, and was created as a multicenter study with 
41	active	centers	at	present,	35	of	which	are	actively	recruiting	(see	






autoantibody in the CSF and/or serum or a hippocampal antibody 
with	unknown	specificity	or	(2)	clinical/paraclinical	indication	of	
immune-mediated	genesis	(response	to	immunosuppression,	in-
trathecal immunoglobulin synthesis, and/or CSF pleocytosis, typ-
ical	MRI	changes	such	as	bitemporal	T2/FLAIR	hyperintensities).
Included patients are locally pseudonymised and documented 
using a server-based database. Epidemiological, clinical and para-
clinical data as well as therapies are recorded. All patients whose 
Introduction
Registry	studies	have	the	advantage	of	flexibility,	longevity	and	ac-
quisition of large amounts of data in a relatively short period of time 
compared to clinical trial interventions, without much loss of evi-
dence.	They	are	particularly	suited	to	document	rare	diseases	and	
pathologies	as	well	as	side	effects,	or	to	characterize	special	patient	
cohorts which cannot be included in clinical intervention studies 
(such	as	pregnant	women).	In	the	past	10	years	several	neuroim-
munological	registries	have	been	created	in	Germany.	Numerous	
neurologists in clinics and practices across the country support reg-






sented as well as initial results and an outlook on further planned 
evaluations will be provided.







and above all morbidity and associated high socioeconomic costs 
[1].	In	recent	years,	the	field	has	experienced	dynamic	development	
by the pioneering description of synaptic autoantibodies as bio-
markers and, in all likelihood, by disease-causing agents [2]. On the 
one hand, the discovery of new synaptic antibodies allows a per-
sistent	therapeutic	and	prognostic	sub-	and	reclassification	of	au-
toimmune encephalitis syndromes [3]; on the other hand, the rapid 
growth of knowledge represents a diagnostic challenge for clini-
cians and scientists. Due to the rarity of the individual encephalit-
ic syndromes, the more precise characterization of clinical phe-
E26
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symptoms began more than three months prior to inclusion are 
placed in a retrospective cohort, while patients exhibiting clinical 
symptoms within the previous three months prior to inclusion are 
grouped in a prospective cohort. Follow-up examinations are per-




tions of clinical and epidemiological as well as prognostic research 
E27
▶Table 1 Overview of neuroimmunological registries.
Registry Disease Focus Number of cases Goals
GENERATE Autoimmune encephalitis Symptomology, 
treatment, progression
570 Epidemiology, progression, prognosis and care 








comparison with MS 
(NationMS)
Approx. 250 Continuing education, consulting and support 
of primary care physicians, patients and 
relatives, multi-sector networking of treating 
physicians
NationMS Clinically isolated syndrome, 
relapsing-remitting multiple 
sclerosis
Long-term observation of 
initially untreated patients 
in early disease stages




Detailed standardized clinical and paraclinical 
data and biomaterial collection as the basis for 
answering	clinical	and	scientific	questions,	risk	
and biomarker discovery and validation
MS registry 
of	the	DMSG
Multiple sclerosis, clinically 
isolated syndrome




On average  > 2.5 
contacts/patient 
per year
Monitoring of care of persons with MS; 
long-term observation of progression 
(therapies);	temporal	changes	in	population;	
patient inclusion, recruitment and research 
platform







DMSKW Multiple sclerosis, clinically 
isolated syndrome, 
neuromyelitis optica
Pregnancy Approx. 1,500 Safety of immune modulating therapies during 
pregnancy and lactation, disease progression 



















individual centers with the possibility of an opt-out provision for 
each	individual	center.	The	structure	and	agreements	within	the	
network have been stipulated in a business regulation.
Results
















orders and intensive medical complications, morphological image 
and neuropsychological aspects as well as therapeutic response 
rates. Likewise promising are an evaluation of long-term process-
es, investigation of patients with early escalation of immunothera-
py as well as prognostic biomarkers in autoimmune encephalitis.
In	February	2017,	the	non-profit	GENERATE	e.V.	was	founded	as	
the organizer and sponsor of the network with the aim of continu-
ing the existing structures. Expansion of the network to centers in 
Austria and Switzerland is in preparation.









all patients [6, 9]. However, NMO is a rare and, to date, little known 




has led to new diagnostic criteria for NMO [12] or NMO spectrum 
disease,	which	can	be	defined	when,	in	addition	to	a	positive	AQP4-
AK serostatus, there is evidence of a primary clinical criterion such 
as optic neuritis, myelitis, cerebral stem syndrome, dysphoric syn-
drome or an unusual cerebral lesion. An additional immunological 













to obtain important information on the epidemiology and the 









In 2008 NEMOS was established as a cross-sector network orient-
ed	toward	clinical	neuroimmunology	designed	specifically	to	ad-
dress physicians active in outpatient and inpatient treatment and 
are	interested	in	clinical	and	scientific	issues	relating	to	NMO.	In	
total, more than two dozen clinics, medical centers and practices 
are	incorporated	into	NEMOS	(▶Fig. 3);	on	the	website	www.
nemos-net.org their activities are recapitulated by two NEMOS co-
ordinators	(currently	T.	Kümpfel,	Ludwig-Maximilians-Universität	
Munich,	and	O.	Aktas,	Heinrich-Heine-Universität	Düsseldorf).	
NEMOS also considers itself vertically open within the medical care 
hierarchy, thus providing opportunities for younger scientists to 
address	relevant	issues.	Until	recently,	scientific	inquiry,	content	
coordination and public relations work were carried out on a vol-
untary	basis	without	structural	or	financial	support,	thus	priority	
was given to retrospective cross-sectional and longitudinal analy-






to interaction with patients as well as with the wider medical pro-
fession/care structure, emphasis is placed on the website, contri-
butions to patient forums and events, the involvement of patient 
organizations as well as information and training programs for neu-
rologists	and	psychiatrists.	The	NEMOS	website,	www.nemos-net.
org,	maintained	by	the	University	Clinic	Düsseldorf	is	certified	ac-
cording to the “Health on the Net” code of conduct for medical and 
health websites, directed toward patients and relatives, interested 
medical personnel as well as the NEMOS centers themselves.
The	original	NEMOS	cohort	accepted	patients	with	NMO,	isolat-
ed	myelitis	and	optic	neuritis	with	AQP4	seropositivity.	The	Nation-
NMO cohort will include patients with NMOSD according to current 
diagnostic	criteria	(IPND	2015),	excluding	patients	with	MS	or	with	
isolated myelitis with MS-typical lesion distribution in a cranial MRI.
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The	original	NEMOS	cohort	recruited	all	NMSOD	patients	includ-
ing those with only single examinations. In the NationNMO cohort 
there will be a prospective examination of patients with incidental 
NMOSD	as	those	with	prevalent	NMSOD.	Thus	the	NationNMO	co-
hort will represent a formal subgroup of the NEMOS cohort.
The	original	NEMOS	cohort	relied	on	a	non-time-limited	collec-




In the NationNMO cohort, a prospective, standardized annual 
clinical and paraclinical data collection will be performed, designed 











Regarding public relations work, relevant stakeholders have been 
gradually approached over the past eight years and the understand-
ing of NMOSD has been deepened as a rare but relevant disease. In 
concrete terms, it was possible to inform interested parties through 
patient events, and through the opportunity of direct contact via 
the NEMOS website, as well as providing support and advice to care 
providers, while directing them to local NMO specialists. Direct 
support opportunities for patients and relatives could be realized 
through participation in the medical advisory board of patient or-
ganizations	such	as	Transverse	Myelitis	e.V.	and	involvement	in	rel-
evant patient forums. Since its founding in 2008, NEMOS has reg-
ularly organized NMO-oriented symposia and workshops for phy-
sicians and other medical personnel at the annual conferences of 
the	German	Neurological	Society	(DGN),	and	has	been	recognized	
for	this	effort	(Felgenhauer	Prize	2014).	The	two	consensus	papers	
on the diagnosis and therapy of NMO should be considered a sign 
of	these	intensive	coordinated	efforts	[11,	13],	which	currently	are	
among the most cited overview articles in this area.
Scientific activity and original work
Since creating its database in 2008, NEMOS has established the 
basis for a number of recognized and internationally published pa-





ing-remitting MS and were routinely put on a high-dose MS ther-
apy with natalizumab [14]; despite this, the patients continued to 
exhibit	persistent	related	disease	activity	[15,	16].	This	difficult	di-
agnosis following a somewhat circuitous route was documented 
in an article on patients who initially underwent a spinal biopsy 
(which	was	in	some	cases	not	acceptably	tolerated)	for	a	suspect-
ed malignant spinal tumor, but who in the end had apparent tume-
factive	longitudinal	extensive	transverse	myelitis	(LETM)	[17].	Fur-
thermore, patients with unusual manifestations of NMOSD in late 
life stages were described using the NEMOS database [18]; addi-
tionally	the	influence	of	gender	on	clinical	aspects	of	NMSOD	was	
characterized [19]. In 2015 NEMOS was able to make a substantial 
contribution regarding acute therapy of NMSOD relapse by demon-
strating the early importance of plasma separation/immune ad-
sorption in particular for longitudinal extensive transverse myelitis 
(LETM)	[20].	Finally,	in	2016	NEMOS	addressed	the	importance	of	
a	systematic	approach	to	anti-MOG	antibodies,	describing	clinical,	
imaging, demographic and immunological aspects [21, 22], as well 
as characterizing brain stem encephalitis which frequently accom-
panies this NMSOD variant [23].
Networking internationally
Right	from	the	start	NEMOS	was	engaged	in	scientific	exchange	
with European and international NMSOD networks. In particular, 
the	initiative	of	the	Guthy-Jackson	Foundation	and	the	regular	
	scientific	conferences	organized	by	this	organization	should	be	
mentioned here. In this context, the path to a common global 
 database for the comprehensive documentation of patients was 
outlined, and increasingly the influence of environmental and 
 lifestyle aspects as well as genetic factors were discussed. It should 
be pointed out that in certain regions such as far east Asia NMOSD 
occurs much more frequently and does not have the status of a rare 
disease [24].
▶Fig. 3	 NEMOS	centers	in	Germany,	November	2016.






is the expansion of a central patient database which allows simple 
input and maintenance of NMOSD patient data on the Internet, 
while	adhering	to	legal	and	ethical	regulations.	This	project	is	sup-
ported by the inclusion of NEMOS as a new partner in the 
BMBF-funded	KKNMS	(as	"NationNMO	cohort"),	which	is	currently	
in	its	third	funding	phase.	This	grant	is	intended	to	support	data-
base-based, standardized patient documentation, fund a clini-
cal-scientific	comparison	of	the	progression	of	the	diseases	and	dif-
ferentiation from MS as a direct reference disease while establish-
ing a central biobank concept. In summary, NEMOS was embedded 
in already existing sustainable structures which made continuation 
of the NEMOS registry possible.
Prospective	Cohort	Study	of	Clinically	









three decades is 83 patients per 100,000 population [26]. MS dis-
ease frequency is higher the more northwards the country is locat-
ed	[27].	The	validation	of	established	risk	factors,	whether	genetic	
or environmental, and uniform data of treatment monitoring algo-
rithms	can	only	be	derived	to	a	limited	extent	from	German	co-




which recruitment started in 2010.
Structure
NationMS is a prospective observational longitudinal cohort study 
(ethics	vote	Ruhr-University	Bochum,	no.	3714-10).
Inclusion	and	exclusion	criteria	are	broadly	defined	in	order	to	
map	the	spectrum	of	the	disease	(▶Table 2 and 3).




with the aim of long-term observation and clinical and paraclinical 
characterization of the patients. Study participants are examined 
in	annual	visits	over	the	first	three	years	and	subsequently	every	
second	year	(▶Fig. 4).	A	deviation	of	3	months	from	the	scheduled	
visit date is accepted.
In addition to the collection of basic demographic and clinical 
data and patient questionnaires, standardized clinical and paraclin-
ical assessment scales are implemented including the assessment 
of the domains of disability, cognition, depression, fatigue and 

























within 24 months prior to inclusion
3)	Therapy-naïve	for	disease-modifying	therapies	(irrespective	of	
relapse	treatment)
▶Table 3 NationMS cohort study exclusion criteria.
NationMS cohort study exclusion criteria
Primary	progressive	multiple	sclerosis	(PPMS)






0 1 2 4 6 8 10
▶Fig. 4 NationMS cohort study design.
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St.	Josef-Hospital	Bochum,	Ruhr-University	Bochum)	performs	
standardized and independent monitoring and review of data.
Results
Recruitment
From August 2010 to December 2014, 1,212 patients were includ-
ed in the NationMS cohort. Due to screening failure or incomplete 
data,	88	patients	(7.3	%)	were	excluded,	resulting	in	1,124	patients	




has been carried out for an extended MRI cohort in centers with 
3-Tesla	MRI.	So	far,	172	patients	have	been	included	in	this	subco-
hort	(as	of	02-Nov-2016).






Scientific activities, original articles, public relations
In addition to the evaluation of baseline clinical data, large-scale 
genetic	projects	have	already	been	significantly	supported	with	
DNA material of the cohort and successfully published [32, 33]. 
Nine	risk	genes	within	the	human	leukocyte	antigen	(HLA)	region	
and seven outside the HLA region were thus replicated within this 
German	population	[32].	In	a	further	study,	four	new	susceptibili-
ty	genes	were	identified;	their	genetic	products	seem	to	be	in-
volved in epigenetic regulation [33].
In	addition	to	scientific	investigations,	the	collaboration	within	
the KKNMS has led to consented recommendations addressing 
therapy monitoring for immunotherapies as well as the issue of the 
change	of	therapy	[34,	35].	This	contributes	to	improvement	of	pa-




ardized clinical and paraclinical assessment and biomaterial. At 
present, the detailed analysis of baseline data including demogra-
phy	and	disease	characteristics	of	this	German	MS	cohort	is	ongo-
ing. Further follow-up and ongoing recruitment are crucial for con-
tinued long-term observation.
Further	current	projects	investigate	relationships	between	clin-
ical parameters and established environmental markers with the 
use of biomaterial. For example, an investigation of vitamin D sta-
tus within the cohort as well as research of viral factors are running. 
Several groups are focused on the analysis of MRI parameters. Mul-
ticenter evaluations of large patient numbers are facilitated by the 
consensus MRI protocol.
The	NationMS	cohort	facilitates	ongoing	and	planned	longitu-
dinal and cross-sectional investigations. Due to the high number 
of	participants,	both	subgroup	analyses	of	defined	patient	groups	
and	large-scale	projects	are	possible.	The	availability	of	standard-
ized data, biomaterial and MRI data will further expand over time. 
The	NationMS	cohort	has	thus	special	significance	for	the	further	
acquisition of knowledge in MS. Hopefully, these results will rapid-
ly	find	their	way	into	clinical	routine	in	order	to	improve	diagnosis,	
therapy	and	care	of	MS	patients	in	Germany;	this	has	already	begun	
as a result of collaborative work within the network via practice-re-
lated publications.
The	MS	Registry	of	the	DMSG
Despite high and increasingly more expensive costs for the treat-
ment	and	support	of	those	suffering	from	MS,	as	well	as	the	pre-
mature exit from employment of patients with MS, there is still lit-















From 2014 to today: new 
infrastructure and PRO
2010 to 2013: Revision of data model 
and infrastructure – common DMSG and 
KKNMS basic data set – web-based 
documentation software
2004 to 2010: Expansion phase – extension of 
documentation country-wide across 150 centers 
for all care areas – standardized quality reviews
2001 to 2003: Startup phase – principles established 
for uniform documentation of MS with five different 
care areas
▶Fig. 5 Developmental phases of the MS registry since founding 
2001 until now [source-supplied illustration].
1		MS	Forschungs-	und	Projektentwicklungs-gGmbH	a	100	%	subsidiary	of	the	
DMS	Stiftung	of	the	DMSG,	BV	e.V.
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As part of a comprehensive revision in cooperation with the In-
stitute for Medical Informatics of the University Medical Center 
Göttingen,	the	registry	was	methodically	revised	until	2014,	both	
in terms of its infrastructure and the applied data set.
The	current	goal	of	the	MS	registry	is	to	establish	a	permanent	
data repository for care research based on the over 10 years of 
 experience. It will ensure the collection, storage and provision of 








will support the exchange of data with other national and interna-
tional MS repositories. Such collaborations will more intensively 
compare	regional	aspects	or	opportunities	of	different	health	sys-
tems, so that the requirements of individualized medical research 






disease course OR CIS
 ▪ Primary	domicile	in	Germany
The	MS	registry	has	developed	a	nationwide	network	of	MS	centers	
including all areas2	of	care	(see	▶Fig. 6)	that	recruit	MS	patients	
for	the	registry.	These	centers	are	awarded	by	the	DMSG	Bun-
desverband	e.V.3.	The	broad	network	enables	the	included	patients	
to be comprehensively documented crossing center and sector bar-
riers, thus supporting the current focus on longitudinal observa-
tion of disease progression.
The	centers	involved	in	the	MS	registry	are	currently	being	mi-
grated from decentralized data collection to a centralized, web-
based	documentation	platform.	The	previously	documented	data	
are being transferred to the new infrastructure using a migration 
tool. After two years of transition, since the fourth quarter of 2016, 
the new data set and the documentation in the web-based research 
database are obligatory for all centers. In addition to the web-based 
data entry, documentation can be performed in third-party sys-





to the Internet is necessary to access the documentation platform. 
Corrections	or	additions	to	the	data	set	(for	example,	newly	ap-
proved	active	substances	and	supplementary	items)	can	now	be	
performed centrally and made available to all centers simultane-
ously without delay. Same goes for updates of the platform.
In the web-based research database, the centers receive feed-
back on their documentation via checks of established value rang-
es, plausibility and cross-references in the event of discrepancies. 
These	checks	are	supplemented	by	subsequent	reviews	of	the	 
total	data	pool.	Queries	regarding	the	documented	data	arising	
during monitoring are send out to the centers as integrated que-
ries in the research database and can be answered directly there. 
An audit trail is also available and allows the tracking of changes to 
the data.
The	data	in	the	registry	is	collected	prospectively	and	multi-cen-
trically. It includes data from routine examinations of MS patients. 
Patient	documentation	is	recurrent	and	consists	of	several	mod-
ules	that	are	filled	out	in:
 ▪ Baseline documentation: including basic data such as gender, 
age, initial symptoms and onset of the disease.
 ▪ and continuous follow-up documentations: comprising 





2  74 MS specialty centers, 80 MS centers and 19 MS rehabilitation centers 








includes registry-related additions. In an expansion module, select-




icy will be linked to clinical data in the MS registry. During the revi-
sion, purely clinical data collection was expanded to include the 
patient’s	perspective.	Variables	of	supplementary	issues	can	be	
modularly included in the registry documentation, and the result-






The	registry	follows	the	structure	illustrated	in	▶Fig. 7 which 
has been implemented in accordance with the generic data pro-
tection	concepts	of	the	TMF	e.V.	A	strict	separation	of	identifying	
data	(IDAT)	and	medical	data	is	maintained.	A	link	between	the	
pseudonymized medical and identifying data is only possible for 
the treatment centers in which the patient has given his/her con-
sent to registering.


































37.8 ± 11.2 2.6 ± 3.6 1.5 69.7	%
▶Fig. 7 Inclusion of centers and patients in the documentation of the MS registry in relation to the underlying infrastructure [source-supplied 
illustration][44].
4		The	following	figures	represent	registry	data	as	of	September	2016






2005, the initial results4 were published regarding the uniform data 
set	resulting	from	the	Germany-wide	survey,	providing	informa-
tion regarding distribution according to gender, forms of progres-
sion,	symptoms,	age	at	disease	onset	(average:	32.9	years),	initial	
symptoms	and	time	to	diagnosis	(average	2.7	years).	See	also	ex-





Based on the initial data obtained from the new registry infra-
structure,	the	issue	arising	as	a	result	of	Petersen	et	al.	[46]	was	an-
swered: whether the proportion of patients with primary progres-
sive	MS	(PPMS),	who	receive	a	therapy	to	modify	the	course	of	the	
disease contrary to the current guidelines, is also accounted for in 
the registry. Our evaluation showed a similarly high proportion of 
patients	with	PPMS	receiving	therapy.	However,	we	were	able	to	
demonstrate that compared to earlier observations [40] the pro-
portion has decreased [47].
In addition to cross-sectional observations, the MS registry of-
fers	the	capability	of	long-term	observations.	The	number	of	pa-
tients with coherent documentation over a 3 or 6-year period is 
being continuously expanded and currently stands at more than 
8,300 and 1,000 data sets. In 20155 visits for more than 12,700 pa-
tients were documented. On average there were more than two 
consultations per patient in 2015.
The	MS	registry	is	open	for	research	and	collaborative	projects6. 
For example, available data can be used during the planning phase 
of	research	projects	to	generate	hypotheses,	which,	based	on	the	
new infrastructure and the modular data set can be answered as a 
supplementary	question	via	the	registry	platform	[44].	The	MS	reg-
istry has already successfully established data exchange at the na-
tional and European level.
Outlook
The	available	data	are	currently	being	used	for	additional	issues,	
including “benign MS” and symptoms and provision of therapy, and 
are available for publication.
In the future, reports should regularly be provided to the docu-
menting centers as an overview of their respective populations 
compared to the total population or the population range under 
care, thus supplementing the already available statistics and re-
ports	in	the	research	database.	A	related	pilot	project	is	currently	
underway, providing the centers with a better overview of their pa-
tient	data.	In	this	way,	for	example,	special	characteristics	(e.	g.,	in-
creased	proportion	of	progressive	patients)	can	be	identified.	In	
the past, such data have already been requested by the centers in 








registries to establish a system to provide the supervisory author-





new medications have been approved in recent years. New approv-
als	concerned	in	particular	the	field	of	highly	active	immunothera-
pies	[48].	Additional	Phase	III	studies	have	been	completed	or	are	
still underway [49] so that additional approvals can be expected in 
coming	years.	While	frequent	side	effects	are	usually	recognized	
prior	to	approval	in	Phase	II	and	III	studies,	less	common	side	effects	
are often not known at the time of approval because of limited pa-
tient	numbers.	An	efficient	post-approval	pharmacovigilance	sys-
tem is therefore of great importance. Since the immune system is 




therapy registry for recording the incidence, type and characteris-
tics of adverse events of current and future immunotherapeutic 
agents in MS therapy. Secondary goals include analysis of factors 
that	increase	the	risk	of	drug	side	effects	as	well	as	those	associat-
ed with good therapy adherence.
Structure
The	registry	includes	patients	with	a	confirmed	MS	diagnosis	or	CIS	




mide, dimethyl fumarate, daclizumab or a drug released in the fu-
ture regardless of duration of therapy; or those who have been 
treated with interferons, glatiramer acetate or azathioprine for a 
maximum of 36 months.
REGIMS	is	a	multicentric	registry	of	the	KKNMS,	which	is	coor-
dinated	at	the	Westfälische	Wilhelms-Universität	Münster.	Partic-
ipating centers are clinics, MS outpatient clinics and MS specialty 
centers that include patients in routine screening.
Data collection includes electronic documentation of medical 
parameters collected at participating centers by trained personnel 
as	well	as	patient	documentation	in	which	the	patient	fills	out	a	
questionnaire.	The	basic	medical	documentation	includes	current	
and previous MS therapies, comorbidities, EDSS scores, relapses 
and	any	pregnancies.	The	patients	are	tracked	by	follow-up	every	
six	months.	The	medical	follow-up	documentation	includes	relaps-
es since the last examination, changes in MS therapy, reasons for 
discontinuation of therapy, adverse and serious adverse events as 
well as pregnancies. In addition, the patient receives questions on 5  Data collection and assessment for 2016 is not yet complete.
6		Please	direct	related	questions	to	the	MSFP	(msregister@dmsg.de).
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are also cooperation partners of the KKNMS.
Unwanted events of current and future immunotherapeutic 
agents	are	thus	detected	at	an	early	stage	(typically	at	occurrence)	
and	reported	to	the	manufacturers.	The	narrow	time	frames	for	the	
documentation as well as a parallel survey of both patient and phy-
sician	guarantee	this.	This	makes	an	overall	picture	of	the	disease	
and patient situation possible. In addition, centers and their pa-
tients have the option to participate in the biobank of the KKNMS. 
For this purpose, there is a separate consent procedure and a stand-
ardized method for blood collection and shipment. After accept-





After successful establishment of the immunotherapy registry since 
the	start	of	the	project	in	2013,	the	number	of	new	participating	
centers is steadily rising, and new patients are increasingly includ-
ed in the respective centers. In addition, the semiannual medical 
follow-up surveys are carried out in the centers, allowing the de-
scription	of	medical	information	regarding	MS	therapy	(including	
changes	in	therapy),	the	course	of	the	disease,	side	effects	and	co-
morbidities. At the same time, every six months participating pa-





700 patients. In the course of the coming months additional 
centers	will	join.
Outlook
Establishment of a pharmacovigilance database for MS medications 
is	significant	due	to	the	approval	of	numerous	new	drugs	to	treat	
MS as well as the fact that additional medicines are in the approval 
process.	An	immunotherapy	registry	offers	important	advantages,	
especially	with	respect	to	the	long-term	effects	of	medicinal	prod-
ucts. Country-wide recruiting of additional centers is currently in 
progress. In addition, collaboration with the MSBase international 
registry	(www.msbase.org)	[50]	is	in	preparation	as	well	as	with	the	
Swedish	MS	registry	SMSreg	[51]	so	that	side	effects	can	be	record-
ed, assessed and reported on a broad basis.




In recent years, only a few diseases have experienced such a great 






ing clinical trials, but also after market introduction, only limited 






glatiramer acetate [53]. Data on more than 300 pregnancies was 
collected	for	natalizumab	[54]	and	fingolimod	[55]	exposed	preg-
nancies.	There	is	insufficient	experience	with	newer	substances	
such as teriflunomide, dimethyl fumarate, alemtuzumab and 
 daclizumab to evaluate the safety of exposure to these therapies 
during pregnancy.
In addition to safety aspects, the course of MS during pregnan-
cy	and	postpartum	as	well	as	the	identification	of	modifiable	risk	
factors	affecting	relapse	are	of	interest.	The	typical	course	of	MS	





of such therapies before a planned pregnancy on relapse during 
pregnancy	and	postpartum	has	not	been	sufficiently	investigated	
yet. It is known that after discontinuation of natalizumab severe 
rebound relapses can occur [59, 60], and that they can also occur 
during	pregnancy,	despite	its	protective	effect	[61].	Whether	this	
also	applies	to	other	DMTs	which	are	used	for	highly	active	disease	




regimen for MS patients with the desiring to have children in order 
to minimize the risk for both, mother and child.
Structure
The	DMSKW	is	a	prospective	cohort	study	of	pregnant	MS	patients.	
Every year, approximately 250 pregnant women with CIS, clinical-
ly	verified	MS	or	NMO	are	admitted	to	the	registry	at	any	time	dur-
ing pregnancy. Similar to an embryotoxicological advisory insti-
tute, the registry is contacted by treating neurologists, gynecolo-
gists, pediatricians, MS nurses, but also by patients themselves with 
questions regarding pregnancy and MS, especially regarding deal-
ing	with	MS	therapies	before,	during	and	after	pregnancy.	The	ma-




ments in articles of magazines, publications on the homepage 




Data is collected in standardized interviews, generally by tele-
phone.	To	avoid	recall	bias,	interviews	are	conducted	once	during	
every remaining trimester after study entry and in months 1, 3, 6, 
12	and	24	postpartum	(see	▶Fig. 8).	In	addition	to	basic	charac-
teristics of the mother, all data pertaining to drug exposure prior 
and during pregnancy is collected, as well as information relating 
to	progression	of	the	disease,	pregnancy	and	birth.	Progression	of	
MS as well as child development are surveyed up to 2 years after 
birth.	To	limit	information	bias,	data	were	obtained	from	official	
documents such as the maternity log, the child examination record 
as well as the vaccination record. In case of negative pregnancy out-
comes or occurrence of MS relapses during pregnancy or postpar-
tum, gynecologists, pediatricians and neurologists are contacted 
to verify the collected data. All congenital malformations are as-
sessed	and	classified	by	a	teratologist	of	the	Mainz	birth	registry	
according to the current European surveillance of congenital ab-
normalities	(EUROCAT)	guidelines.
Results
In recent years, the DMSKW was able to answer many practically 
relevant questions by targeted data evaluation, and thereby to con-




negative pregnancy outcome, compared to pregnancies not ex-
posed	to	DMTs.	These	results	reflect	the	pharmacologically	plausi-
ble	safety	of	exposure	to	glatiramer	acetate,	interferon-β	or	natal-
izumab during early pregnancy.
In a case series of 13 pregnancies of 12 women with highly-ac-
tive MS treated with natalizumab during the third trimester, 10 out 
of 13 newborns had mild to moderate anomalies such as anemia, 
thrombocytopenia or leukocytosis [68].




Furthermore, the evaluation of women with moderate disease 
activity, who breastfed exclusively, partially breastfed or who did 
not breastfeed at all indicated that only exclusive breastfeeding re-
duced postpartal relapse activity [70], resulting in the hypothesis 
that the anti-ovulation factor, together with pronounced hormo-
nal	changes	contributes	to	this	effect.	In	addition	it	was	observed	
that the reduction of relapse activity ends with the introduction of 
supplemental feeding.
In	recent	years	the	findings	of	the	DMSKW	have	been	able	to	im-
prove the counseling and care of MS patients worldwide wishing 
to	become	pregnant.	Thus	the	summary	of	product	characteristics	
of natalizumab has included a statement regarding hematological 
abnormalities after exposure during the third trimester and result-




Although the DMSKW has contributed substantially to the improve-
ment of MS patients with the desire to have children, a number of 
questions	remain	unanswered	such	as	the	risk	of	interferon-β	or	
glatiramer acetate exposure during the second and third trimes-
ters of pregnancy. In addition, the risk of exposure to newer ther-
apies	such	as	teriflunomide,	dimethyl	fumarate,	alemtuzumab	and	
daclizumab	during	the	first	trimester	needs	to	be	studied.	Also	of	
great interest is the risk of relapse after discontinuation of MS ther-
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Pregnancy Postpartal phase
▶Fig. 8	 Phases	of	the	pregnancy	registry	during	pregnancy	and	postpartum.
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with highly active diseases. It may be feasible to reduce relapses 
during pregnancy and lessen the need for high doses of glucocor-
ticoids by maintaining MS therapy until the onset of pregnancy. 
Low	doses	of	prednisolone	(20	mg)	are	associated	with	a	risk	of	cleft	
palate [71]. It is still unknown whether high dose treatments 
(1000	mg)	are	associated	with	the	risk	of	other	abnormalities.	It	is	
also unclear whether exclusive breastfeeding also has a positive ef-
fect on the risk of relapse in women with highly active disease as 
well	as	the	effects	of	DMT	exposure	during	lactation	on	the	infant.	
The	influence	of	DMT	exposure	during	pregnancy	is	also	uncertain	
on the development and health of children up to the preschool age. 
To	date,	the	DMSKW	has	collected	data	on	the	development	and	
health of 232 small children in an unsystematic, cross-sectional ob-
servation. In the long term, however, it is planned to expand sys-
tematic DMSKW data collection to a 6-year follow-up.
Conclusions
Observational studies are an important part of epidemiological re-
search. Registry studies have become an indispensable means of 
gaining knowledge, especially regarding data collection within spe-
cific	patient	groups,	such	as	patients	with	very	rare	diseases	(or-
phan	diseases)	or	pregnant	women.	The	most	important	advan-
tages of these studies include the possibility to make statements 
about the progress of the disease in connection with therapeutic 
decisions	and	the	related	spectrum	of	side	effects,	multicentric	col-
laboration as well as the support of registry work by contributions 
by	colleagues	in	practice	and	research.	Significant	scientific	ques-
tions can be answered through the collection of clinical data in 
combination with radiological or serological parameters.
Over the past 10 years the six registries presented in this article 
have	established	themselves	across	Germany,	providing	prac-
tice-related results not only for neurologists but also for those af-
fected	by	neurological	diseases.	The	findings	based	on	these	reg-
istries are almost unique and therefore of great importance espe-
cially for patients suffering from rare NMOSD or autoimmune 
encephalitis, but also for the special patient group of women with 
MS who wish to become pregnant.
All neuroimmunological registries presented here work closely 
with colleagues in research and practice, engage actively in public 
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